Article
Biochemistry & Molecular Biology
Ciara Murphy, Gloria Gornes Pons, Anna Keogh, Lisa Ryan, Lorraine Mccarra, Chris Maria Jose, Shagun Kesar, Siobhan Nicholson, Gerard J. Fitzmaurice, Ronan Ryan, Vincent Young, Sinead Cuffe, Stephen P. Finn, Steven G. Gray
Summary: This study investigated the expression and potential clinical utility of JADE2 in non-small cell lung cancer (NSCLC). The results showed that JADE2 expression is significantly altered in NSCLC and high expression of JADE2 is associated with better overall survival. The study also identified associations between JADE2 expression and tumor mutational burden and immune cell infiltration, as well as potential new drugs targeting JADE2. Overall, JADE2 may have potential diagnostic, prognostic, and therapeutic implications in NSCLC.
Review
Immunology
Miguel Garcia-Pardo, Teresa Gorria, Ines Malenica, Stephanie Corgnac, Cristina Teixido, Laura Mezquita
Summary: Immunotherapy has revolutionized the oncology field and become a new standard of care for NSCLC. However, not all patients benefit from immunotherapy, and there is a need for further strategies to improve outcomes. Therapeutic cancer vaccines have the potential to boost antitumor immunity and work synergistically with immune checkpoint inhibitors. However, current vaccine immunization strategies for lung cancer have been unsuccessful. The success of COVID-19 vaccines raises hope that a similar strategy can be successful in cancer treatment.
Review
Biochemistry & Molecular Biology
Aaron C. Tan, Nick Pavlakis
Summary: The management of advanced lung cancer has been transformed by the identification of targetable oncogenic driver alterations, including ALK gene rearrangements. ALK tyrosine kinase inhibitors have become the first-line treatment options for advanced ALK rearranged NSCLC. However, drug resistance remains a challenge, and the role of anti-angiogenic therapy in ALK rearranged NSCLC needs further exploration.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Immunology
Li-Chung Chiu, Shu-Min Lin, Yu-Lun Lo, Scott Chih-Hsi Kuo, Cheng-Ta Yang, Ping-Chih Hsu
Summary: Early-stage NSCLC patients face high risks of recurrence and death even after surgery, with limited improvements from traditional treatments like chemotherapy and radiation. Immunotherapies, including immune checkpoint inhibitors and cancer vaccination, have shown potential in improving survival rates and are being actively researched in clinical trials.
Review
Biochemistry & Molecular Biology
Calogera Claudia Spagnolo, Giuliana Ciappina, Elisa Giovannetti, Andrea Squeri, Barbara Granata, Chiara Lazzari, Giulia Pretelli, Giulia Pasello, Mariacarmela Santarpia
Summary: In recent years, the development of therapeutic agents targeting actionable oncogenic drivers in metastatic non-small cell lung cancer (NSCLC) has increased. Selective inhibitors, such as tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, have shown promising results in patients with MET deregulation, specifically exon 14 skipping mutations or MET amplification. This review provides an overview of MET signaling pathways, oncogenic alterations, laboratory techniques for detection, clinical data and ongoing studies on MET inhibitors, resistance mechanisms, and potential strategies for improving outcomes in MET-exon 14-altered NSCLC patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Letter
Medicine, General & Internal
Hollis Viray, Deepa Rangachari, Daniel B. Costa
Summary: The study reported initial data of trastuzumab deruxtecan in the treatment of lung cancers with ERBB2 mutations, including patients who had previously received ineffective ERBB2 tyrosine kinase inhibitors.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Pharmacology & Pharmacy
Chetna Gupta, Aadya Jaipuria, Nikesh Gupta
Summary: Cancer, particularly lung cancer, is a major cause of mortality. The current primary methods of treatment for lung cancer include oral and systemic drug administration, radiotherapy, and chemotherapy. However, these methods have limitations such as adverse effects, toxicity, and resistance. To overcome these challenges, pulmonary drug delivery systems have been developed, allowing localized delivery of drugs to cancer cells and reducing systemic toxicities. Nano-based systems also provide additional diagnostic advantages. However, pulmonary delivery is still in the early stages of development and various factors need to be considered for the development of suitable inhalable nano-based chemotherapeutic drugs. This review article focuses on inhalable formulations for targeted drug delivery and discusses various devices used in pulmonary drug delivery.
Article
Pharmacology & Pharmacy
Suyash M. Patil, Shruti S. Sawant, Nitesh K. Kunda
Summary: This study developed inhalable BQ-loaded cubosome nanocarriers for NSCLC treatment, showing enhanced therapeutic effects and aerosolization performance compared to free BQ.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2021)
Article
Medicine, Research & Experimental
Bei Zhang, Zhiyao Ren, Jianfu Zhao, Yue Zhu, Boya Huang, Chanchan Xiao, Yan Zhang, Jieping Deng, Lipeng Mao, Lei Tang, Dan Lan, Lijuan Gao, Hongyi Zhang, Guobing Chen, Oscar Junhong Luo
Summary: This study identified candidate T-cell receptors (TCRs) that can target HLA-A2 restricted MAGE-A3 tumor antigen. The researchers screened tumor epitopes and characterized corresponding TCRs using various techniques. They found that these TCRs could induce the activation and cytotoxicity of CD8+ T cells and exhibited strong recognition and killing effect on MAGE-A3+ tumor cells.
Review
Pharmacology & Pharmacy
Stefanie Ho Yi Chan, Yasmin Khatib, Sherael Webley, Deborah Layton, Sam Salek
Summary: In the last few decades, cancer therapies and detection strategies have rapidly developed, resulting in decreased cancer-related death rates. However, cardiovascular disease has emerged as the second leading cause of morbidity and mortality among cancer survivors. Cardiotoxicity from anticancer drugs can affect the heart's function and structure, leading to the development of cardiovascular disease.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Immunology
David S. Hong, Ajay K. Gopal, Alexander N. Shoushtari, Sandip P. Patel, Aiwu R. He, Toshihiko Doi, Suresh S. Ramalingam, Amita Patnaik, Shahneen Sandhu, Ying Chen, Craig B. Davis, Timothy S. Fisher, Bo Huang, Kolette D. Fly, Antoni Ribas
Summary: This study aimed to estimate the objective response rate of utomilumab in patients with immune checkpoint inhibitor-refractory melanoma and non-small-cell lung cancer. The results showed that utomilumab had good tolerability but low antitumor activity. Efficacy was associated with immune-active tumor microenvironments.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
John V. Heymach, David Harpole, Tetsuya Mitsudomi, Janis M. Taube, Gabriella Galffy, Maximilian Hochmair, Thomas Winder, Ruslan Zukov, Gabriel Garbaos, Shugeng Gao, Hiroaki Kuroda, Gyula Ostoros, Tho V. Tran, Jian You, Kang-Yun Lee, Lorenzo Antonuzzo, Zsolt Papai-Szekely, Hiroaki Akamatsu, Bivas Biswas, Alexander Spira, Jeffrey Crawford, Ha T. Le, Mike Aperghis, Gary J. Doherty, Helen Mann, Tamer M. Fouad, Martin Reck, AEGEAN Invest
Summary: In resectable non-small-cell lung cancer patients, perioperative durvalumab plus neoadjuvant chemotherapy showed significantly improved event-free survival and pathological complete response compared to neoadjuvant chemotherapy alone, with a similar safety profile.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Health Care Sciences & Services
Maja Sutic, Ana Vukic, Jurica Baranasic, Asta Foersti, Feda Dzubur, Miroslav Samarzija, Marko Jakopovic, Luka Brcic, Jelena Knezevic
Summary: Lung cancer is the leading cause of cancer-related deaths globally, with most patients still being diagnosed at an advanced stage despite screening efforts for high-risk populations. In the past decade, management of lung cancer has significantly progressed towards personalized treatments, with molecular biomarkers playing a crucial role in prognosis and predicting therapy response. Non-small cell lung cancer, being the most common type, is the primary focus for discussion on promising new biomarkers in clinical management.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Oncology
Mariya Tikhomirova, Iuliia Topchu, Aleksandra Mazitova, Vitaly Barmin, Ekaterina Ratner, Alexey Sabirov, Zinaida Abramova, Alexander Y. Deneka
Summary: This study reveals a novel role for the scaffolding protein NEDD9 in regulating DNA damage response signaling and sensitivity to DNA damaging therapies in lung cancer. Experimental results demonstrate that NEDD9 depletion enhances ATM-CHK2 signaling, leading to cellular phenotype transition and increased sensitivity to UV irradiation. Furthermore, immunohistochemical analysis finds an association between reduced NEDD9 protein expression and decreased overall survival of lung cancer patients.
Article
Oncology
Xueru Zhu, Yiting Wang, Chang Jiang, Xiaoyang Li, Linying Sun, Guangzhong Wang, Xiaolong Fu
Summary: This study explored the intrinsic radiosensitivity of non-small cell lung cancer (NSCLC) and identified radiosensitivity-specific proteins that can guide individualized radiation therapy. The study also validated the functions of these proteins in NSCLC cell lines and delineated the atlas network of NSCLC radiosensitivity-related signaling pathways, which could further contribute to the understanding of the underlying mechanism.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Review
Immunology
Xiangye Zhao, Kewei Ma, Xiaobo Ma, Xu Wang, Chao Sun, Shi Qiu, Ye Guo, Zhiguang Yang, Yunpeng Liu, Yinghui Xu
Summary: Immunotherapy may lead to pseudoprogression, where tumors initially grow but shrink with continued treatment. This article reports a case of pseudoprogression in a lung cancer patient receiving immunotherapy, and reviews the mechanisms, clinical manifestations, and prognostic indicators of pseudoprogression.
Article
Immunology
Ling-zhijie Kong, Ying Zheng, Kaichun Li
Summary: Treatment options for metastatic colorectal cancer are limited after second-line chemotherapy failure. In this case report, a 59-year-old male patient achieved remarkable response to fruquintinib and toripalimab combination therapy after multiple lines of chemotherapy failed. The patient had partial response within 3 months and complete response of pulmonary masses within 12 months. The combination of fruquintinib and PD-1 inhibitors improves the prognosis of metastatic colorectal cancer, with a progression-free survival of over 17 months.
